# A Rollover Protocol for Subjects Previously Treated With AGS-003

> **NCT01482949** · PHASE2 · TERMINATED · sponsor: **Argos Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** AGS-003

## Key facts

- **NCT ID:** NCT01482949
- **Lead sponsor:** Argos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482949, "A Rollover Protocol for Subjects Previously Treated With AGS-003". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01482949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*